Induction and maintenance of bi-functional (IFN-γ + IL-2+ and IL-2+ TNF-α+) T cell responses by DNA prime MVA boosted subtype C prophylactic vaccine tested in a Phase I trial in India
Effective vaccine design relies on accurate knowledge of protection against a pathogen, so as to be able to induce relevant and effective protective responses against it. An ideal Human Immunodeficiency virus (HIV) vaccine should induce humoral as well as cellular immune responses to prevent initial...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Public Library of Science
2019
|
| _version_ | 1797072631083565056 |
|---|---|
| author | Munusamy Ponnan, S Pattabiram, S Thiruvengadam, K Goyal, R Singla, N Mukherjee, J Chatrath, S Bergin, P Kopycinski, J Gilmour, J Kumar, S Muthu, M Subramaniam, S Swaminathan, S Prasad Tripathy, S Luke, H |
| author_facet | Munusamy Ponnan, S Pattabiram, S Thiruvengadam, K Goyal, R Singla, N Mukherjee, J Chatrath, S Bergin, P Kopycinski, J Gilmour, J Kumar, S Muthu, M Subramaniam, S Swaminathan, S Prasad Tripathy, S Luke, H |
| author_sort | Munusamy Ponnan, S |
| collection | OXFORD |
| description | Effective vaccine design relies on accurate knowledge of protection against a pathogen, so as to be able to induce relevant and effective protective responses against it. An ideal Human Immunodeficiency virus (HIV) vaccine should induce humoral as well as cellular immune responses to prevent initial infection of host cells or limit early events of viral dissemination. A Phase I HIV-1 prophylactic vaccine trial sponsored by the International AIDS Vaccine Initiative (IAVI) was conducted in India in 2009.The trial tested a HIV-1 subtype C vaccine in a prime-boost regimen, comprising of a DNA prime (ADVAX) and Modified Vaccine Ankara (MVA) (TBC-M4) boost. The trial reported that the vaccine regimen was safe, well tolerated, and resulted in enhancement of HIV-specific immune responses. However, preliminary immunological studies were limited to vaccine-induced IFN-γ responses against the Env and Gag peptides. The present study is a retrospective study to characterize in detail the nature of the vaccine-induced cell mediated immune responses among volunteers, using Peripheral Blood Mononuclear Cells (PBMC) that were archived during the trial. ELISpot was used to measure IFN-γ responses and polyfunctional T cells were analyzed by intracellular multicolor flow cytometry. It was observed that DNA priming and MVA boosting induced Env and Gag specific bi-functional and multi-functional CD4+ and CD8+ T cells expressing IFN-γ, TNF-α and IL-2. The heterologous prime-boost regimen appeared to be slightly superior to the homologous prime-boost regimen in inducing favorable cell mediated immune responses. These results suggest that an in-depth analysis of vaccine-induced cellular immune response can aid in the identification of correlates of an effective immunogenic response, and inform future design of HIV vaccines. |
| first_indexed | 2024-03-06T23:10:33Z |
| format | Journal article |
| id | oxford-uuid:654e9843-fb9b-4130-b2ef-f502d14f3e3a |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T23:10:33Z |
| publishDate | 2019 |
| publisher | Public Library of Science |
| record_format | dspace |
| spelling | oxford-uuid:654e9843-fb9b-4130-b2ef-f502d14f3e3a2022-03-26T18:24:44ZInduction and maintenance of bi-functional (IFN-γ + IL-2+ and IL-2+ TNF-α+) T cell responses by DNA prime MVA boosted subtype C prophylactic vaccine tested in a Phase I trial in IndiaJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:654e9843-fb9b-4130-b2ef-f502d14f3e3aEnglishSymplectic Elements at OxfordPublic Library of Science2019Munusamy Ponnan, SPattabiram, SThiruvengadam, KGoyal, RSingla, NMukherjee, JChatrath, SBergin, PKopycinski, JGilmour, JKumar, SMuthu, MSubramaniam, SSwaminathan, SPrasad Tripathy, SLuke, HEffective vaccine design relies on accurate knowledge of protection against a pathogen, so as to be able to induce relevant and effective protective responses against it. An ideal Human Immunodeficiency virus (HIV) vaccine should induce humoral as well as cellular immune responses to prevent initial infection of host cells or limit early events of viral dissemination. A Phase I HIV-1 prophylactic vaccine trial sponsored by the International AIDS Vaccine Initiative (IAVI) was conducted in India in 2009.The trial tested a HIV-1 subtype C vaccine in a prime-boost regimen, comprising of a DNA prime (ADVAX) and Modified Vaccine Ankara (MVA) (TBC-M4) boost. The trial reported that the vaccine regimen was safe, well tolerated, and resulted in enhancement of HIV-specific immune responses. However, preliminary immunological studies were limited to vaccine-induced IFN-γ responses against the Env and Gag peptides. The present study is a retrospective study to characterize in detail the nature of the vaccine-induced cell mediated immune responses among volunteers, using Peripheral Blood Mononuclear Cells (PBMC) that were archived during the trial. ELISpot was used to measure IFN-γ responses and polyfunctional T cells were analyzed by intracellular multicolor flow cytometry. It was observed that DNA priming and MVA boosting induced Env and Gag specific bi-functional and multi-functional CD4+ and CD8+ T cells expressing IFN-γ, TNF-α and IL-2. The heterologous prime-boost regimen appeared to be slightly superior to the homologous prime-boost regimen in inducing favorable cell mediated immune responses. These results suggest that an in-depth analysis of vaccine-induced cellular immune response can aid in the identification of correlates of an effective immunogenic response, and inform future design of HIV vaccines. |
| spellingShingle | Munusamy Ponnan, S Pattabiram, S Thiruvengadam, K Goyal, R Singla, N Mukherjee, J Chatrath, S Bergin, P Kopycinski, J Gilmour, J Kumar, S Muthu, M Subramaniam, S Swaminathan, S Prasad Tripathy, S Luke, H Induction and maintenance of bi-functional (IFN-γ + IL-2+ and IL-2+ TNF-α+) T cell responses by DNA prime MVA boosted subtype C prophylactic vaccine tested in a Phase I trial in India |
| title | Induction and maintenance of bi-functional (IFN-γ + IL-2+ and IL-2+ TNF-α+) T cell responses by DNA prime MVA boosted subtype C prophylactic vaccine tested in a Phase I trial in India |
| title_full | Induction and maintenance of bi-functional (IFN-γ + IL-2+ and IL-2+ TNF-α+) T cell responses by DNA prime MVA boosted subtype C prophylactic vaccine tested in a Phase I trial in India |
| title_fullStr | Induction and maintenance of bi-functional (IFN-γ + IL-2+ and IL-2+ TNF-α+) T cell responses by DNA prime MVA boosted subtype C prophylactic vaccine tested in a Phase I trial in India |
| title_full_unstemmed | Induction and maintenance of bi-functional (IFN-γ + IL-2+ and IL-2+ TNF-α+) T cell responses by DNA prime MVA boosted subtype C prophylactic vaccine tested in a Phase I trial in India |
| title_short | Induction and maintenance of bi-functional (IFN-γ + IL-2+ and IL-2+ TNF-α+) T cell responses by DNA prime MVA boosted subtype C prophylactic vaccine tested in a Phase I trial in India |
| title_sort | induction and maintenance of bi functional ifn γ il 2 and il 2 tnf α t cell responses by dna prime mva boosted subtype c prophylactic vaccine tested in a phase i trial in india |
| work_keys_str_mv | AT munusamyponnans inductionandmaintenanceofbifunctionalifngil2andil2tnfatcellresponsesbydnaprimemvaboostedsubtypecprophylacticvaccinetestedinaphaseitrialinindia AT pattabirams inductionandmaintenanceofbifunctionalifngil2andil2tnfatcellresponsesbydnaprimemvaboostedsubtypecprophylacticvaccinetestedinaphaseitrialinindia AT thiruvengadamk inductionandmaintenanceofbifunctionalifngil2andil2tnfatcellresponsesbydnaprimemvaboostedsubtypecprophylacticvaccinetestedinaphaseitrialinindia AT goyalr inductionandmaintenanceofbifunctionalifngil2andil2tnfatcellresponsesbydnaprimemvaboostedsubtypecprophylacticvaccinetestedinaphaseitrialinindia AT singlan inductionandmaintenanceofbifunctionalifngil2andil2tnfatcellresponsesbydnaprimemvaboostedsubtypecprophylacticvaccinetestedinaphaseitrialinindia AT mukherjeej inductionandmaintenanceofbifunctionalifngil2andil2tnfatcellresponsesbydnaprimemvaboostedsubtypecprophylacticvaccinetestedinaphaseitrialinindia AT chatraths inductionandmaintenanceofbifunctionalifngil2andil2tnfatcellresponsesbydnaprimemvaboostedsubtypecprophylacticvaccinetestedinaphaseitrialinindia AT berginp inductionandmaintenanceofbifunctionalifngil2andil2tnfatcellresponsesbydnaprimemvaboostedsubtypecprophylacticvaccinetestedinaphaseitrialinindia AT kopycinskij inductionandmaintenanceofbifunctionalifngil2andil2tnfatcellresponsesbydnaprimemvaboostedsubtypecprophylacticvaccinetestedinaphaseitrialinindia AT gilmourj inductionandmaintenanceofbifunctionalifngil2andil2tnfatcellresponsesbydnaprimemvaboostedsubtypecprophylacticvaccinetestedinaphaseitrialinindia AT kumars inductionandmaintenanceofbifunctionalifngil2andil2tnfatcellresponsesbydnaprimemvaboostedsubtypecprophylacticvaccinetestedinaphaseitrialinindia AT muthum inductionandmaintenanceofbifunctionalifngil2andil2tnfatcellresponsesbydnaprimemvaboostedsubtypecprophylacticvaccinetestedinaphaseitrialinindia AT subramaniams inductionandmaintenanceofbifunctionalifngil2andil2tnfatcellresponsesbydnaprimemvaboostedsubtypecprophylacticvaccinetestedinaphaseitrialinindia AT swaminathans inductionandmaintenanceofbifunctionalifngil2andil2tnfatcellresponsesbydnaprimemvaboostedsubtypecprophylacticvaccinetestedinaphaseitrialinindia AT prasadtripathys inductionandmaintenanceofbifunctionalifngil2andil2tnfatcellresponsesbydnaprimemvaboostedsubtypecprophylacticvaccinetestedinaphaseitrialinindia AT lukeh inductionandmaintenanceofbifunctionalifngil2andil2tnfatcellresponsesbydnaprimemvaboostedsubtypecprophylacticvaccinetestedinaphaseitrialinindia |